Search Results - "ETOH, Takuma"

  • Showing 1 - 16 results of 16
Refine Results
  1. 1
  2. 2

    A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure by SPINALE, Francis G, COKER, Mytsi L, HEUNG, Lena J, BOND, Brian R, GUNASINGHE, Himali R, ETOH, Takuma, GOLDBERG, Aron T, ZELLNER, James L, CRUMBLEY, A. Jackson

    Published in Circulation (New York, N.Y.) (17-10-2000)
    “…Matrix metalloproteinases (MMPs) contribute to matrix remodeling in disease states such as tumor metastases. Extracellular matrix metalloproteinase inducer…”
    Get full text
    Journal Article
  3. 3

    One-year effectiveness and safety of open-label losartan hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors by Kita, Toshihiro, Yokota, Naoto, Ichiki, Yoshinari, Ayabe, Takao, Etoh, Takuma, Tamaki, Noboru, Kato, Johji, Eto, Tanenao, Kitamura, Kazuo

    Published in Hypertension research (01-04-2010)
    “…The long-term antihypertensive efficacy and safety of losartan/hydrochlorothiazide (HCTZ) combinations have not been appropriately evaluated in Japan. In this…”
    Get full text
    Journal Article
  4. 4

    Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure by PETERSON, J. Thomas, HALLAK, Hussein, JOHNSON, Linda, HUA LI, O'BRIEN, Patrick M, SLISKOVIC, Drago R, BOCAN, Thomas M. A, COKER, Mytsi L, ETOH, Takuma, SPINALE, Francis G

    Published in Circulation (New York, N.Y.) (08-05-2001)
    “…Matrix metalloproteinase (MMP) activation contributes to tissue remodeling in several disease states, and increased MMP activity has been observed in left…”
    Get full text
    Journal Article
  5. 5

    Differences in 24-h blood pressure profile of Japanese hypertensive patients under ARB treatment by Kita, Toshihiro, Sakima, Atsushi, Yokota, Naoto, Tamaki, Noboru, Etoh, Takuma, Shimokubo, Toru, Nakada, Seigo, Takishita, Shuichi, Ohya, Yusuke, Kitamura, Kazuo

    “…Blood pressure (BP) control throughout the entire day is recommended for cardiovascular protection. Angiotensin-II receptor blockers (ARBs) are widely used in…”
    Get full text
    Journal Article
  6. 6

    Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs by Etoh, T, Joffs, C, Deschamps, A M, Davis, J, Dowdy, K, Hendrick, J, Baicu, S, Mukherjee, R, Manhaini, M, Spinale, F G

    “…A structural event during the evolution of a myocardial infarction (MI) is left ventricular (LV) remodeling. The mechanisms that contribute to early changes in…”
    Get more information
    Journal Article
  7. 7

    Matrix metalloproteinase expression and activity in isolated myocytes after neurohormonal stimulation by Coker, M L, Jolly, J R, Joffs, C, Etoh, T, Holder, J R, Bond, B R, Spinale, F G

    “…Changes in myocardial matrix metalloproteinase (MMP) activity and expression have been associated with left ventricular (LV) remodeling. A recent study…”
    Get more information
    Journal Article
  8. 8

    Synergistic effect of chronic kidney disease and high circulatory norepinephrine level on stroke risk in Japanese hypertensive patients by Yano, Yuichirou, Hoshide, Satoshi, Etoh, Takuma, Tamaki, Noboru, Yokota, Naoto, Kario, Kazuomi

    Published in Atherosclerosis (01-11-2011)
    “…Abstract Objective Evidence is now available about the association between chronic kidney disease (CKD) and stroke. However, less is known about the underlying…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13

    Atrial and brain natriuretic peptides as markers of cardiac load and volume retention in primary aldosteronism by Kato, Johji, Etoh, Takuma, Kitamura, Kazuo, Eto, Tanenao

    Published in American journal of hypertension (01-03-2005)
    “…Atrial and brain natriuretic peptides (ANP and BNP, respectively) are cardiac hormones with natriuretic and vasodilator actions. The present study was carried…”
    Get full text
    Journal Article
  14. 14

    Plasma adrenomedullin concentration in patients with heart failure by KATO, J, KOBAYASHI, K, ETOH, T, TANAKA, M, KITAMURA, K, IMAMURA, T, KOIWAYA, Y, KANGAWA, K, ETO, T

    “…We measured plasma concentrations of adrenomedullin (AM), a novel bioactive peptide with potent vasodilator activity, in 21 patients with chronic congestive…”
    Get full text
    Journal Article
  15. 15

    Increased plasma adrenomedullin levels in chronic congestive heart failure by Kobayashi, Kohji, Kitamura, Kazuo, Etoh, Takuma, Nagatomo, Yoshitatsu, Takenaga, Makoto, Ishikawa, Tadashi, Imamura, Takuroh, Koiwaya, Yasushi, Eto, Tanenao

    Published in The American heart journal (01-05-1996)
    “…Adrenomedullin is a potent vasodilator peptide and occurs in circulating blood of human beings and experimental animals. Because it is produced in intact aorta…”
    Get full text
    Journal Article
  16. 16

    Differential hormonal profiles of adrenomedullin and proadrenomedullin n‐terminal 20 peptide in patients with heart failure and effect of treatment on their plasma levels by Etoh, Takuma, Kato, Johji, Takenaga, Makoto, Imamura, Takuroh, Kitamura, Kazuo, Koiwaya, Yasushi, Eto, Tanenao

    Published in Clinical cardiology (Mahwah, N.J.) (01-02-1999)
    “…Background: Adrenomedullin (AM) is a potent vasodilatory peptide discovered in human pheochromocytoma tissue. Proadrenomedullin N‐terminal 20 peptide (PAMP)…”
    Get full text
    Journal Article